RT Journal Article SR Electronic T1 Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.16.20132597 DO 10.1101/2020.06.16.20132597 A1 Emilie Sbidian A1 Julie Josse A1 Guillaume Lemaitre A1 Imke Meyer A1 Mélodie Bernaux A1 Alexandre Gramfort A1 Nathanaël Lapidus A1 Nicolas Paris A1 Antoine Neuraz A1 Ivan Lerner A1 Nicolas Garcelon A1 Bastien Rance A1 Olivier Grisel A1 Thomas Moreau A1 Ali Bellamine A1 Pierre Wolkenstein A1 Gaël Varoquaux A1 Eric Caumes A1 Marc Lavielle A1 Armand Mekontso Dessap A1 Etienne Audureau A1 On behalf of AP-HP/Universities/Inserm COVID-19 research collaboration A1 AP-HP Covid CDR Initiative and ‘Entrepôt de Données de Santé’ AP-HP consortium YR 2020 UL http://medrxiv.org/content/early/2020/06/19/2020.06.16.20132597.abstract AB Objective To assess the clinical effectiveness of oral hydroxychloroquine (HCQ) with or without azithromycin (AZI) in preventing death or leading to hospital discharge.Design Retrospective cohort study.Setting An analysis of data from electronic medical records and administrative claim data from the French Assistance Publique - Hôpitaux de Paris (AP-HP) data warehouse, in 39 public hospitals, Ile-de-France, France.Participants All adult inpatients with at least one PCR-documented SARS-CoV-2 RNA from a nasopharyngeal sample between February 1st, 2020 and April 6th, 2020 were eligible for analysis. The study population was restricted to patients who did not receive COVID-19 treatments assessed in ongoing trials, including antivirals and immunosuppressive drugs. End of follow-up was defined as the date of death, discharge home, day 28 after admission, whichever occurred first, or administrative censoring on May 4, 2020.Intervention Patients were further classified into 3 groups: (i) receiving HCQ alone, (ii) receiving HCQ together with AZI, and (iii) receiving neither HCQ nor AZI. Exposure to a HCQ/AZI combination was defined as a simultaneous prescription of the 2 treatments (more or less one day).Main outcome measures The primary outcome was all-cause 28-day mortality as a time-to-event endpoint under a competing risks survival analysis framework. The secondary outcome was 28-day discharge home. Augmented inverse probability of treatment weighted (AIPTW) estimates of the average treatment effect (ATE) were computed to account for confounding.Results A total of 4,642 patients (mean age: 66.1 ± 18; males: 2,738 (59%)) were included, of whom 623 (13.4%) received HCQ alone, 227 (5.9%) received HCQ plus AZI, and 3,792 (81.7%) neither drug. Patients receiving ‘HCQ alone’ or ‘HCQ plus AZI’ were more likely younger, males, current smokers and overall presented with slightly more co-morbidities (obesity, diabetes, any chronic pulmonary diseases, liver diseases), while no major difference was apparent in biological parameters. After accounting for confounding, no statistically significant difference was observed between the ‘HCQ’ and ‘Neither drug’ groups for 28-day mortality: AIPTW absolute difference in ATE was +1.24% (−5.63 to 8.12), ratio in ATE 1.05 (0.77 to 1.33). 28-day discharge rates were statistically significantly higher in the ‘HCQ’ group: AIPTW absolute difference in ATE (+11.1% [3.30 to 18.9]), ratio in ATE (1.25 [1.07 to 1.42]). As for the ‘HCQ+AZI’ vs neither drug, trends for significant differences and ratios in AIPTW ATE were found suggesting higher mortality rates in the former group (difference in ATE +9.83% [-0.51 to 20.17], ratio in ATE 1.40 [0.98 to 1.81];p=0.062).Conclusions Using a large non-selected population of inpatients hospitalized for COVID-19 infection in 39 hospitals in France and robust methodological approaches, we found no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality. Our results suggested a possible excess risk of mortality associated with HCQ combined with AZI, but not with HCQ alone. Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies. Altogether, our findings further support the need to complete currently undergoing randomized clinical trials.What is already known on this subject- The use of Hydroxychloroquine (HCQ) or HCQ with azithromycin (AZI) has been associated with viral load reduction at 6 days in COVID-19 infected patients- No difference between HCQ and no-HCQ groups in terms of risk of death or need for mechanical ventilation was found in two large cohorts of hospitalized COVID-19 infected patientsWhat this study adds- Using a large non-selected population of inpatients hospitalized for COVID-19 infection in 39 hospitals in France and robust methodological approaches, we found no evidence for efficacy of HCQ on 28-day mortality- Our results suggest an excess risk of mortality in patients treated by a combination of HCQ and AZI, but not with HCQ alone- Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studiesCompeting Interest StatementArmand Mekontso Dessap reports research grants from Fischer Paykel, Baxter, Philips, Ferring and GSK, participation to advisory board for Air liquid, Baxter, and Amomed, lectures for Getingu and Addmedica, all outside the scope of the submitted work, Etienne Audureau reports consulting for consulting GBT and HEMANEXT (both protocol design of an unrelated work in hematology). The other authors : no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the French data protection agency Commission Nationale de l Informatique et des Libertes (regulatory decision DE-2017-013), IRB00011591. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available on request after publication.